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Abstract
Cells with sphere forming capacity, spheroid cells, are present in the malignant ascites of patients with epithelial ovarian
cancer (EOC) and represent a significant impediment to efficacious treatment due to their putative role in progression,
metastasis and chemotherapy resistance. The exact mechanisms that underlie EOC metastasis and drug resistance are not
clear. Understanding the biology of sphere forming cells may contribute to the identification of novel therapeutic
opportunities for metastatic EOC. Here we generated spheroid cells from human ovarian cancer cell lines and primary
ovarian cancer. Xenoengraftment of as few as 2000 dissociated spheroid cells into immune-deficient mice allowed full
recapitulation of the original tumor, whereas .105 parent tumor cells remained non-tumorigenic. The spheroid cells were
found to be enriched for cells with cancer stem cell-like characteristics such as upregulation of stem cell genes, self-renewal,
high proliferative and differentiation potential, and high aldehyde dehydrogenase (ALDH) activity. Furthermore, spheroid
cells were more aggressive in growth, migration, invasion, scratch recovery, clonogenic survival, anchorage-independent
growth, and more resistant to chemotherapy in vitro. 13C-glucose metabolic studies revealed that spheroid cells route
glucose predominantly to anaerobic glycolysis and pentose cycle to the detriment of re-routing glucose for anabolic
purposes. These metabolic properties of sphere forming cells appear to confer increased resistance to apoptosis and
contribute to more aggressive tumor growth. Collectively, we demonstrated that spheroid cells with cancer stem cell-like
characteristics contributed to tumor generation, progression and chemotherapy resistance. This study provides insight into
the relationship between tumor dissemination and metabolic attributes of human cancer stem cells and has clinical
implications for cancer therapy.
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Introduction
Epithelial ovarian cancer (EOC) is the leading cause of death
from gynecologic malignancies. There are more than 23,000 cases
annually in the United States, and 14,000 women can be expected
to die from the disease [1]. Despite modest improvements in
response rates, progression-free and median survival using
adjuvant platinum and taxane chemotherapy following cytore-
ductive surgery, overall survival rates for patients with advanced
EOC and ovarian-like malignancies (primary peritoneal) remain
disappointing [2]. This has been attributed to several reasons.
First, in contrast to most other solid tumors, more than 75% of
EOC patients present with advanced stage disease (FIGO III or
IV). Secondly, although most patients initially respond to platinum
and paclitaxel chemotherapy including complete responses, the
relapse rate is approximately 85%. Within 2 years of cytoreductive
surgery and systemic chemotherapy, tumors usually recur and
once relapse occurs, curative therapy is difficult. Therefore, it is
imperative to understand the mechanism(s) of EOC metastasis and
chemotherapy resistance in order to improve clinical outcomes in
this disease.
The primary mode of distant metastasis in EOC involves the
shedding of cells from the primary tumor, into the abdominal
cavity, followed by implantation on the mesothelial lining of the
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peritoneum [3,4]. Currently, there are data to demonstrate that
‘‘sphere forming cells’’ or ‘‘spheroids’’ are commonly found in
ascites and are capable of tumorigenesis in vivo, have a reduced
response to chemotherapeutic drugs in vitro, and may play an
important role in metastatic disease [5–9]. Because metabolic
changes may confer an advantage on the ability of cancer cells to
survive, proliferate, and invade [10–12], we hypothesized that
sphere forming cells are likely to exhibit metabolic attributes that
promote their ability to survive and metastasize. In present study,
we generated spheroid cells from EOC cell lines and from patients
with primary ovarian cancer. Our in vivo and in vitro biologic
studies suggested that these sphere forming cells are enriched in
cancer stem-like cells (CSCL) that critically contribute to ovarian
cancer tumorigenesis, metastasis and chemotherapy resistance. We
then utilized isotope-based dynamic metabolic profiling [13,14], to
simultaneously assess the substrate flux within and among major
metabolic pathways of macromolecule synthesis and energy
production under various physiologic conditions. We found that
spheroid cells increase anaerobic glycolysis and pentose cycle and
decrease re-routing of glucose for anabolic purposes. This study
provides insights into the relationship between tumor dissemina-
tion and metabolic attributes of ovarian CSCL cells, and has
clinical implications for cancer therapy.
Materials and Methods
Isolation of Tumor Cells from Human Ovarian Cancer
Tumor specimens and ascitic fluid were obtained from patients
undergoing tumor debulking surgery for epithelial ovarian cancer
(EOC) at Roswell Park Cancer Institute (RPCI), Buffalo, NY. All
specimens were collected under an approved protocol CIC 02–15
from the Institutional Review Board at RPCI, and informed
written consent was obtained from each patient. Tumor cells from
ascites were obtained from centrifuged cell pellets of ascitic fluid.
The pellets were washed twice in PBS, placed on Ficoll-Hypaque
density gradients and centrifuged again to harvest tumor cells. To
obtain tumor cells from solid tumor tissue, tumor specimens were
finely minced in cell culture medium and single cell suspensions
were washed twice in PBS followed by Ficoll-Hypaque purifica-
tion.
Cell Culture
Primary EOC cell lines were established from solid tumor and
ascites by culturing cells in 13 different conditions [15,16] from 30
EOC patients over a period of 2 years. Spheroid cells were
generated from new EOC cell lines and from an established
ovarian cancer cell line, OV2774, which were obtained from
Sloan Kettering Institute, New York, NY (courtesy of Lloyd J. Old,
Ludwig Institute for Cancer Research, NY), by the method as
described [17] with modifications by resuspending 86104 cells
with serum-free DMEM/F12 supplemented with 10 ng/mL
human recombinant epidermal growth factor (EGF; Invitrogen),
10 ng/mL basic fibroblast growth factor (bFGF; Invitrogen), and
N2 supplement-A (Stemcell Technologies Inc) in Ultra Low
Attachment 6-well plates (Corning) and subsequent organization
into spheres.
In vivo Xenograft Experiments
All animal studies adhered to protocols approved by the
Institutional Animal Care and Use Committee of RPCI.
Dissociated spheroid or parent tumor cells were counted,
resuspended in 50 mL 1:1 RPMI/Matrigel (BD Biosciences), and
injected subcutaneous (s.c.) into the right legs of 3- to 4-wk-old
female SCID mice (C.B-igh-1blcrTac-Prkdcscid/Ros) provided by
RPCI Animal Facility (originated from Taconic Farms, Hudson,
NY). Engrafted mice were inspected biweekly for tumor appear-
ance by visual observation and palpation, and tumor latencies
were determined. Mice were sacrificed by cervical dislocation at a
tumor diameter of 1 cm or at 6 months post-transplantation.
Xenograft tumors were resected, fixed in 10% neutral, buffered
formalin, and embedded in paraffin for sectioning (5 mm) on a
rotary microtome, followed by slide mounting, H&E staining, and
histologic assessment by a pathologist for tumor type, grade, and
stage. To determine xenograft recapitulation of the parental tumor
phenotype, the same process was performed on human tumors. To
evaluate formation of ovarian tumors in their native environment,
SCID mice were injected intraperitoneal (i.p.) with various
amounts of spheroid-derived cells or their parent tumors,
monitored biweekly for weight change and ascites formation,
and euthanized upon excessive abdominal distention or palpable
tumor growth.
Stem Cell Marker Gene Expression Profiling
Signosis’s Human stem cell marker cDNA plate array was used
to examine stem cell related gene expression on spheroid cells and
parent cells according to the manufacturer’s protocol. Briefly, total
RNA isolated from cells by Tri Reagent (Molecular Research
Center, Inc.) was reverse transcribed into cDNA, which was
hybridized with gene-specific oligonucleotide pre-coated in indi-
vidual wells. The expression level of genes was detected by
chemiluminescent signals by a plate reader.
Quantitative PCR
Total RNA was exacted from spheroid or non-spheroid cells
using Qiagen’s RNeasy Mini Kit per manufacture’s procedure and
reverse transcribed into cDNA by iScript cDNA Synthesis Kit
from Bio-Rad. Quantitative real-time PCR was performed using
Bio-Rad’s iQ SYBR Green Supermix per company’s protocols in
a iCycler iQ system also from Bio-Rad. Real-time PCR primer
sequences are shown in Table 1. Thermal cycling was performed
by an initial denaturing step at 95uC for 3 min followed by 40
cycles of denaturation at 95uC for 10 sec, then 60uC for 1 min for
annealing and data collection. Melt-curve analysis was performed
immediately after the amplification protocol under the following
conditions: 80 cycles of 0.5uC increments (10 sec each) beginning
at 57.5uC (data collection step). Each experiment was performed
in triplicate, with normalization to the ribosomal protein L4
(RPL4) gene as an internal control and target gene expression level
was calculated by DDCt method using Bio-Rad’s iQ5 quantitative
PCR analysis software.
ALDH Activity Analysis
The ALDEFLUOR kit (StemCell Technologies, Vacouver,
Canada) uses a fluorescent substrate which accumulates within
cells after oxidized by ALDH enzyme. Cells in a concentration of
26105/ml were stained by 5 ml ALDEFLUOR reagent at 37uC
for 45 min. In each experiment, a sample of cells was stained
under identical conditions with specific ALDH inhibitor diethy-
laminobenzaldehyde (DEAB) as negative control for setting up
flow cytometry gate. The BioVision ALDH Activity Assay kit
(BioVision) quantifies ALDH enzymatic activity by absorbance
reading at 450 nm. Acetaldehyde is oxidized by ALDH generating
NADH which then reduces a colorless probe to a colored product.
Spheroid cells or parental cells (16106) were lysed by 200 ml
ALDH Assay Buffer and 10 ml of the cell lysate were used for the
assay. OD450s were read at 10 min and 1 hr intervals and ALDH
activities were calculated according to manufacturer’s protocol. All
tests were done in duplicate.
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Proliferation Assay
Parental and spheroid EOC cells were cultured in complete
medium (CM, 10%FBS+RPMI) or unsupplemented RPMI for
24 h. Then the same amounts of cells were seeded in tissue culture
plate with CM, half of the medium was changed every 3 days and
cell growth was detected by CellTiter-Glo Luminescent Cell
Viability Assay as described [18] (Promega Corp). The prolifer-
ation assays were done in triplicate.
Migration Assay
Parental and spheroid EOC cells were treated with unsupple-
mented RPMI for 24 h. In a transwell plate, 26105/well cells were
put into insert with 0.2%BSA-RPMI medium, the chamber has no
cells except RPMI medium with 2.5% FBS. After culture for 1, 2,
and 3 days, the numbers of cells that passed through membrane as
well as cells fall into chamber were calculated under microscope
after 10% formaldehyde fixing for 20 min followed by 0.1%
crystal blue staining for another 20 min both at room temperature
(RT). All tests were done in duplicate.
Wound Healing (Scratch) Assay
Parental and spheroid EOC cells were cultured in CM for 24 h.
Then cells were seeded into 6-well plates to 80–90% confluence
and the cell monolayer was scratched in a straight line with a
200 ml pipette tip to create a ‘‘scratch’’. Debris was removed with
PBS and then the culture was re-fed with fresh medium. Images
were taken at 0 and 24 hr after the scratch to calculate the cell
migration rate.
Invasion Assay
Parental and spheroid EOC cells were treated with RPMI only
medium for 24 h. In a transwell plate, 40000/well cells were put
into insert which is coated with matrigel in 0.2%BSA-RPMI
medium, the chamber has no cells except RPMI medium with 5%
FBS. After culture for 1, 2, and 3 days, inserts were collected and
the surface of membranes were cleaned, cells in matrigel were
fixed by 10% formaldehyde for 20 min RT and the numbers of
cells that invaded into matrigel were determined after staining with
0.1% crystal blue 20 min RT. All experiments were done in
duplicate.
Anchorage-independent Growth Assay
Five hundred cells were seeded in triplicate in 6-well plates
containing a top layer of 0.3% soft agar and a 0.5% agar base in
DMEM, 10% FBS. Twenty-four hours later, the average number
of cells seeded per field was determined by counting cells in 5
different fields under the light microscope. Colonies formed
(.0.1 mm in diameter) after 3 weeks of growth in soft agar were
counted; 10 different fields were quantified per well and the
average number of colonies per field was calculated. The AIG
(anchorage-independent growth) index was expressed relative to
the number of cells seeded.
Chemotherapy Resistance Assay
Spheres were dissociated by trypsinization and pipetting and
cells were seeded at 5,000 cells per well (96-well plates; Corning) in
200 mL CM medium. All cells were treated for 24 h with 0 to
6 mg/mL Cisplatin (BD Biosciences) or 0 to 18 mg/mL Paclitaxel
(Sigma; n= 5 per drug dose). Relative cell numbers were
determined by CellTiter-Glo Luminescent Cell Viability Assay
[18]. Dose-response experiments were performed in duplicate.
Percentage cell survival is expressed relative to untreated control.
Spheroid cell drug cytotoxicities were compared after 48-h
treatment with Cisplatin (4 mg/mL). After drug treatments, cells
were incubated for 8 days in drug-free CM medium and cell
colonies were examined under microscopy.
Clonogenic Survival Assay
Cells were treated with various amounts of Cisplatin for 24 h.
After removing the drug, cells were washed with PBS, harvested
and 300 of surviving cells/well were re-fed with CM medium in 6-
well plate. 10–14 days later, colonies were stained with 0.1%
crystal violet and counted.
Immunohistochemistry
Tumor specimens were fixed with buffered formalin and
embedded in paraffin. Sections (5 mm) were placed on glass slides,
heated at 60uC for 20 min, and then deparaffinized with xylene
and ethanol. For antigen retrieval, tumor specimens mounted on
glass slides were immersed in preheated antigen retrieval solution
(DAKO high pH solution; DAKO, Carpinteria, CA) for 20 min
and allowed to cool for 20 min at room temperature. After the
inactivation of endogenous peroxidase, purified specific monoclo-
nal antibody CA125 (Ov 185:1, Novocastra) (1:200 dilution) and
CK7 (Dako) (1:20 dilution or 75 mg/ml) were then added, and
incubated overnight at 4uC. The primary antibody was detected
with a biotinylated anti-mouse IgG (DAKO). Diaminobenzidine
tetrahydrochloride was then added for development for 10 min,
followed by counterstaining with hematoxylin solution.
Biochemical Analyses
The use of [U-13C6] glucose tracer in combination with mass
spectrometry allows the evaluation of metabolic flux through the
main pathways facilitating energy production and biosynthetic
metabolism of the cell. Normal ovarian cells (RPNLOv78) were
kindly provided by Dr. T Pejovic [19]. The cells were cultured in
1:1 mixture of RPMI and DMEM (glucose-free) +10% FBS
+10 ug/ml Insulin +10 ng/ml EGF+0.1% Gentamicin+
Table 1. Quantitate real time PCR primers used in this study.
Type Sequence
Notch1
ACC# NM_017617.3 Forward GGGACCAACTGTGACATCAA
Reverse GTAGCCACTGGTCATGTCTTT
CD34
ACC# NM_001773.2 Forward TAGCCTGTCACCTGGAAATG
Reverse TGCCTTGATGTCACTTAGGATAG
Cdcp1
ACC# AF468010.1 Forward AAGGACACAGACATTCCCTTAC
Reverse GTCTCAGTGCCCTGCTTTAT
Nanog
ACC# NM_024865.2 Forward TCCTGAACCTCAGCTACAAAC
Reverse GCGTCACACCATTGCTATTC
Myc
ACC# NM_002467.4 Forward CTTCTCTGAAAGGCTCTCCTTG
Reverse GTCGAGGTCATAGTTCCTGTTG
RPL4
ACC# AK294113.1 Forward GGCTACAAGAAGACCAAGGAA
Reverse CTCATTCGCTGAGAGGCATAG
doi:10.1371/journal.pone.0084941.t001
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[U-13C6]glucose (180 mg/ml). Parent cells (RP-OV17534) were
cultured in RPMI (glucose-free) +10%FBS+[U-13C6]glucose
(180 mg/ml). RP-OV17534 spheroid cells were cultured in
DMEM/F12 (glucose-free) +N2 Supplement-A +EGF 10 ng/ml
+bFGF 10 ng/ml+[U-13C6]glucose (180 mg/ml). After 24 hrs of
the incubation, cells were centrifuged (1,500 rpm for 5 minutes)
and incubation medium and cell pellets were obtained. Glucose
and lactate incubation medium concentrations were determined as
previously described [20]. Lactate from the cell culture media was
extracted by ethyl acetate after acidification with HCl. Lactate
was derivatized to its propylamide-heptafluorobutyric form and
the m/z 330 and 331 (carbons 2–3 of lactate, chemical ionization)
was monitored for the detection of m2 (13C double-labeled lactate)
and m3 (triple-labeled lactate) for the estimation of pentose cycle
activity versus anaerobic glycolysis [21]. Glutamate was separated
from the medium using ion-exchange chromatography [22].
Glutamate was converted to its n-trifluoroacetyl-n-butyl derivative
and the ion clusters m/z 198 (carbons 2–5 of glutamate, electron
impact ionization) were monitored. 13CO2 release was measured
by a Finnegan Delta-S ion ratio mass spectroscope and was used to
estimate glucose carbon utilization through oxidation by the cell
lines [23]. Mass spectral analyses were carried out by three
independent automatic injections by the sampler and accepted
only if the standard sample deviation was ,1% of the normalized
peak intensity.
Data Analysis and Statistical Methods
Statistical analyses were done using the parametric unpaired,
two-tailed independent sample t test with 99% confidence
intervals.
Results
Generation of Spheroid Cells from Primary Ovarian
Cancer Specimens and Established EOC Cell Lines
Stable cell lines were established successfully from 3 of 30 (10%)
cultures initiated from primary EOC specimens over a period of 2
years. RP-OV15526 was derived from solid tumor while RP-
OV17534 and RP-OV313777 were derived from EOC ascites.
These cells have been cultured in vitro for 465, 312, and 125 days
with 68, 65, and 17 passages, respectively. All lines were from late-
stage (IIIC or IV) ovarian serous adenocarcinoma cancer patients.
Confluent monolayer of primary human EOC cells depicted
typical epithelial cobblestone morphology with 3-dimensional
growing upwards in cell-condensed areas (Fig. 1A). Examination
Figure 1. Spheroid cells were generated from primary and established EOC cells. (A) Three primary cell lines generated from EOC patients
show epithelial cells morphology. (B) One of primary EOC cell line generated 3-D independent, self-renewing spheroid cells under stem-cell selection
media. (C) Primary cell lines express ovarian carcinoma marker CA-125 and epithelial marker CK-7, as shown by IHC for RP-OV17534. (D) EOC cell line
OV2774 is able to generate OV2774 spheroid cells (E). All scale bar unit in this figure and following figures are in mm.
doi:10.1371/journal.pone.0084941.g001
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of epithelial markers CK-7 and CA-125 further confirmed the
epithelial nature of these primary cell lines (Fig. 1C). In order to
generate spheroid cells, ovarian cancer cell line OV2774 or
primary EOC cells were enzymatically dissociated and inoculated
on ultra-low attachment culture plates in serum-free medium with
EGF, bFGF, and N2 supplement-A. In this culture condition some
cells died from serum starvation, while others were forced into
suspension and formed aggregates. Three weeks after plating,
some aggregates compacted into spheres which could not be
dissociated by pipetting. Some of the spheres also aggregated to
form sphere clusters. Floating spheres and clusters were dissociated
by pipetting, and replated twice a week, with the resulting cells
generating secondary spheres, appearing as distinct prototypical
spheroids (Figs. 1B, 1E), similar to those found in patient ascites
[5,6]. Using this approach, we obtained sustainable spheroids from
established cell line OV2774 (Figs. 1D and 1E) and primary
EOC cells RP-OV17534 (Figs. 1A and 1B) under stem-selective
conditions. We have cultured the OV2774 and RP-OV17534 cells
as spheroids for 6 months, demonstrating the self-renewing ability
of the spheroid cells.
Spheroid Cells Tumorigenicity and Metastasis in
Immune-deficient Mice
Next, we investigated the tumorigenicity of sphere-forming cells.
We examined whether exponentially smaller numbers (compared
with parental cancer cells) were capable of tumorigenesis, as
previously shown for other epithelial cancer initiating cells (CICs)
[24–28]. Spheroid cells or corresponding parental bulk tumor cells
were injected s.c. into right legs of SCID mice. With injections of
only 2,000 cells per mouse, spheroid cells were tumorigenic in 4 of
4 SCID mice for RP-OV17534 spheroid cells and 2 of 2 for
OV2774 spheroid cells, as evidenced by palpable tumors at the
injection site (Fig. 2A; Table 2). The median tumor latency time
in this cohort was 31 to 90 days for RP-OV17534 spheroid and 50
to 57 for OV2774 spheroid, similar to or less than CICs of other
malignancies [24–27]. Correspondingly, injections of 5,000 and
10,000 RP-OV17534 spheroid cells were also tumorigenic in three
of three mice with shorter tumor latencies (Fig. 2A; Table 2).
Without non-adherent spheroid selection, bulk tumor cells failed
to form tumors even at 40,000 cells for RP-OV17534 engraftment
(Table 2). All subcutaneous xenograft tumors derived from
spheroid cells were categorized as serous adenocarcinomas of
moderate/poor differentiation (grade 2/grade 3), similar to the
Figure 2. RP-OV17534 Spheroid cells generated tumors in immune-deficient mice. (A) Different amount of spheroid cells s.c. injected into
SCID mice formed tumors. (B) Spheroid cells i.p. injected into SCID mice formed bloody ascites and tumors in different organs as indicated by arrows.
(C) Representative H&E staining sections (upper panel) shows RP-OV17534 primary tumor, subcutaneous graft tumor from spheroids, intraperitoneal
graft tumor from spheroids, and serial intraperitoneal graft tumor from SCID mouse ascites. Histological analysis (lower panel) shows frequent
metastasis of tumor cells into various organs of spheroid cells recipients.
doi:10.1371/journal.pone.0084941.g002
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parental primary patient tumors (H&E stained sections; Fig. 2C).
No architectural/cytologic differences were observed between
primary and graft tumors.
A major limitation of studies of CICs is engraftment into non-
native microenvironments [29,30]. To establish that CICs
faithfully recapitulate the well-established progression of ovarian
cancer in its native setting, the experiments were conducted with
intra-peritoneal (i.p.) injections. The i.p. injection of only 10,000
cells per mouse of RP-OV17534 spheroid cells resulted in
development of bloody ascites in 4 of 4 SCID mice (Fig. 2B;
Table 2), with tumor latencies of 75 to 84 days, similar to or less
than CICs of other malignancies [17]. Correspondingly, i.p.
injections of 20,000 and 40,000 spheroid cells were also
tumorigenic in three of three mice with shorter tumor latencies
(Table 2). Without non-adherent spheroid selection, bulk tumor
cells failed to form bloody ascites and tumors even at 80,000 cells
per injection, whereas one of one and 3 of 3 mice i.p. injected
respectively with 1.76107 and 26107 parental primary EOC cells
were tumorigenic, albeit with extended latency (92–105 days;
Table 2). I.p. injection of sphere-forming cells resulted in
development of bloody ascites and peritoneal metastasis to the
omentum, liver, colon, stomach, and kidney (Fig. 2B), and
intraperitoneal tumor histology similar to both subcutaneous
xenograft and primary patient tumors (Fig. 2C). Consistent with
the results for RP-OV17534, we also observed higher tumorige-
nicity of OV2774 spheroid cells compared to their parent cells, in
similar i.p. engraftment animal experiments using OV2774
derived cells (Table 2).
Another essential criterion for CICs is their ability to serially
propagate tumors in consecutively engrafted animals [31]. To
examine this definitive stemness characteristic, serial engraftments
of xenografts were performed. 26104 of spheroid cells were i.p.
injected into SCID mice and ascites developed as expected in 3 out
of 3 mice in approximately 60 days. Transplantation of 86104,
16105, and 56105 such ascites cells into SCID mice resulted in
ascites and tumors, with a latency significantly shorter than the
parental patient tumor cells (66/63/49 days respectively for
passage 2 xenografts versus no tumor development for parent
tumor cells of 86104 transplantation in 0 out of 3 SCID mice).
The pathology of the omental mass was similar to that of s.c.
tumors (Fig. 2C). These results indicate that sphere-forming cells
are more tumorigenic than their parental tumor cells, demon-
strating that a highly tumorigenic subpopulation of cells are
present within the sphere-forming cells, and may reside within
ovarian neoplasms. Since RP-OV17534 spheroid cells and
OV2774 spheroid cells demonstrated similar characteristics, the
following results are shown for RP-OV17534 derived cells with
similar observations for OV2774 cells.
Table 2. In vivo tumorigenicity of ovarian cancer spheroid cells.
Cell type Injection cell type Injection site Cell dosea Tumor formationb Latencyc days
Primary Spheroid S.c. 2000 4/4 31/38/42/90
EOC S.c. 5000 3/3 40/52/54
RP-OV S.c. 10000 3/3 31/37/38
17534 Parental S.c. 5000 0/2 –
S.c. 10000 0/2 –
S.c. 40000 0/2 –
Spheroid I.p. 10000 4/4 75/80/80/84
I.p. 20000 3/3 59/63/63
I.p. 40000 3/3 54/54/63
Parental I.p. 20000 0/2 –
I.p. 40000 0/2 –
I.p. 60000 0/2 –
I.p. 80000 0/3 –
I.p. 1.76107 1/1 92
I.p. 26107 3/3 105
EOC cell Spheroid S.c. 2000 2/2 50/57
line Parental S.c. 2000 1/2 57
OV2774 Spheroid I.p. 5000 1/1 126
I.p. 15000 1/1 85
I.p. 20000 1/1 126
I.p. 300000 1/1 79
Parental I.p. 20000 0/1 –
I.p. 40000 0/1 –
1.26107 1/1 50
26107 1/1 38
aNumber of cells per injection.
bNumber of tumors formed per number of injection.
cThe time from injection to the first appearance of a palpable tumor or ascites.
S.c.: subcutaneous; I.p.: intraperitoneal.
doi:10.1371/journal.pone.0084941.t002
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Figure 3. Spheroid cells overexpressed stem cell genes. (A) Total RNA isolated from spheroid cells and parent cells were examined for their
gene expression by a human stem cell markers cDNA array and stem cell-genes showed higher expression levels in spheroid cells to non-spheroid
cells. (B) The overexpression levels of Notch1, Nanog, Cdcp1, CD34, and Myc in spheroid cells compared to non-spheroid cells were confirmed by
quantitative real-time PCR. These stem cell-genes’ expression were lost or down-regulated when spheroid cells were differentiated by culturing in CM
without growth factors for 14 days. Expression levels are represented as fold changes compared to these of non-spheroid cells. (C) FACS examination
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Ovarian Tumor Sphere-forming Cells Express Stem Cell
Genes
To examine the expression of gene specific to embryonic stem
cells, total RNA from spheroid cells and parent cells were analyzed
by a Human Stem Cell Marker cDNA Plate Array. Among 32
genes tested, spheroid cells upregulated Notch1, Nanog, Cdcp1,
CD34, and Myc expression (Fig. 3A). Each of these genes is
essential for developmental processes (embryogenesis, neurogene-
sis, stem cell expansion, and hematopoiesis [32–34]). These results
were confirmed by quantitative real-time PCR data. The
expression levels of Notch1, Nanog, Cdcp1, CD34, and Myc in
spheroid cells were approximately 10 to 2000 fold higher than that
of non-spheroid cells detected by real-time PCR (Fig. 3B, red
bar). When spheroid cells were cultured in CM without growth
factors, a differentiating condition, floating cells adhered and grew
into epithelial cells. Next we compared the same sets of gene
expression level by real-time PCR in spheroid cells, culturing in
either stem cell-selective or differentiating conditions for 14 days.
Expression of CD34 and Nanog were approximately 1 fold of that
of non-spheroid cells, Cdcp1 and Myc decreased to 9 and 500 fold,
respectively. Notch1 expression level in spheroid cells stayed at 12
fold of that of non-spheroid cells after culturing in CM for 14 days
(Fig. 3B, green bar). Stem cell factor receptor CD117 (c-kit) has
been reported in previous studies on ovarian cancer tumor
progenitors [17,35]. Therefore, we examined CD117 expression
by FACS in these spheroid cells. Consistent with previous reports,
we also detected CD117 up-regulation in spheroid cells compared
with parent cells. Since a large number of spheroid cells killed by
chemotherapy drugs were differentiated non-stem cells, whereas
stem-like cells survived (see below), we found that CD117
expression further increased in spheroid cells after cisplatin
treatment for 24 hrs (Fig. 3C). These data indicate that spheroid
cells from ovarian cancer overexpress stem cell genes under stem
cell-selective conditions and lose or decrease these gene expres-
sions under differentiation conditions.
Increased ALDH Activity in Spheroid Cells
ALDH plays a vital role in cellular detoxification. Recent studies
show that increased ALDH activity leads to several types of
malignancies, serves as a cancer stem cell marker and correlated
with poor prognosis [36–39]. Our ALDEFLUOR assay showed
more ALDH+ cells in spheroid cells in the absence of ALDH
inhibitor DEAB (Fig. 4A). The increased ALDH function in
spheroid cells was confirmed by an ALDH activity colorimetric
assay, showing significant enhanced activity in spheroid cells
(Fig. 4B).
Spheroid Cells have High Proliferation and Migration
Potential than their Parental Cells
The relationship of spheroid formation and cell growth
potential was examined in a kinetic cell proliferation assay.
Increased cell proliferation was demonstrated in spheroid cells
compared with parent cells. More cells appeared at day 6 and
continued increasing to day 17 (Fig. 5A). Since all cell cultures
were maintained at identical growth conditions in the same culture
milieu, their varying growth kinetics could be attributed to cell
intrinsic mechanisms.
Cell motility is one of the factors that contribute to tumor cell
invasion [40]. To detect the migration kinetics of spheroids versus
non-spheroid cells, parental and spheroid EOC cells were studied
in a migration assay. Very few parental cells migrated while
significant amount of spheroid cells passed through transwell
membrane. The difference started to show on day 2 and continued
on day 3 (Fig. 5B). The observation that spheroid cells migrated
quicker than their parental cells was further confirmed by a wound
healing assay. As shown in Figure 5C, more spheroid cells
migrated into the scratch than parental cells. The data also suggest
spheroid cells may utilize different wound healing pathways.
Ovarian Tumor Spheroid Cells Showed Invasion Abilities
and Anchorage-independent Growth
To study the relationship between spheroid formation and cell
invasion, spheroid cells and parental cells were tested in an
of CD117 expression on spheroid cells and parent cells showing high CD117 expression in spheroid cells. Some spheroid cells were treated with
Cisplatin for 24 hrs before surface staining by CD117 Abs. Error bars: SD, N = 3. *: p,0.05.
doi:10.1371/journal.pone.0084941.g003
Figure 4. Increased ALDH activity in spheroid cells. (A) The ALDEFLOUR kit labels the population with a high ALDH enzymatic activity in
spheroid cells. An aliquot of each sample of cells was treated with ALDH inhibitor DEAB as negative control for setting FACS gate. (B) The BioVision
ALDH colorimetric assay detected enhanced ALDH activity in spheroid cell lysate. Error bars: SD, N = 2. *: p,0.05.
doi:10.1371/journal.pone.0084941.g004
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invasion assay. In this assay, cells need to break down matrigel
while in migration assay cells just moved through a membrane.
The invasion assay mimics the in vivo situation more closely. As
shown in Figure 5D, very few parent cells invaded into matrigel
while significantly more spheroid cells invaded into matrigel after
3 days of culture. Spheroid cells had higher invasion ability than
their parental cells detected on day 1, 2, and 3 (Fig. 5E). Since
spheroid cells show increased proliferation ability after 6 days of
culture in proliferation assay, it is unlikely that the superior
invasion ability of spheroid cells is merely due to their higher
proliferation property. This in vitro invasion potential is consistent
with the observed in vivo spheroid cells tumorigenicity as shown in
Fig. 2. To further confirm the aggressive properties of spheroid
cells, we next investigated their tumorigenic potential using the
anchorage-independent growth (AIG) assay. Fig. 5F shows that
parent cells could not form colony in soft agar while spheroid cells
produced significant numbers of colonies, providing additional
evidence for the increased tumorigenic attributes of spheroid cells.
Spheroid Cells are Resistant to Conventional
Chemotherapies
To determine whether spheroid cells possess a cancer stem cell
chemoresistant phenotype, spheroid cells and parent cells were
treated in the same serum-free culture medium for 24 h. After
which, 5000/well of cells was treated by various amounts of
Cisplatin in CM. Numbers of cells were determined by CellTiter-
Glo Luminescent Cell Viability Assay at different time points.
More spheroid cells were killed by Cisplatin at concentrations
above 4 mg/mL on day2 while only few non-spheroid cells were
dead at the same concentrations, suggesting that spheroid cells are
initially more sensitive to Cisplatin than non-spheroid cells due to
their proliferation potential (Fig. 6A). However, when cells treated
with Cisplatin for 48 h were washed and cultured in CM for
another 8 days, spheroid cells formed more colonies than non-
spheroid cells (Fig. 6B). These results suggested that a large
number of spheroid cells killed by Cisplatin are differentiated
Figure 5. Spheroid cells show a more aggressive growth pattern. (A) Spheroid cells had higher proliferation potential than their parent cells.
Both spheroid cells and parental cells were cultured in CM for 24 h, then 5000/well cells were cultured in CM in 96 well plates. Half of media was
changed every 3 days. Cell proliferations were detected from day 0 to day 17 by CellTiter-Glo Luminescent Cell Viability Assay. (B) Spheroid cells had
higher migration ability than parent cells. Parental and spheroid EOC cells were treated with RPMI only medium for 24 hrs. In a transwell plate,
26105/well cells were put into insert with 0.2%BSA-RPMI medium, the lower chamber contains no cells except RPMI medium with 2.5% FBS. After
culture for 1, 2, and 3 days, the numbers of cells that passed through membrane as well as cells fall into chamber were calculated under microscope.
(C) Spheroid cells recovered ‘scratch’ made by 200-mL pipette tip after 24 hours more efficient than their parent cells. Experiments were repeated
three times with similar results. (D) More spheroid cells invaded into matrigel than parent cells as shown by microscopy. Spheroid cells and parental
cells were treated with serum-free medium RPMI for 24 h. In a transwell plate, 40000/well of cells were put into insert coated with matrigel with 0.2%
BSA, while the chamber had only media with 5% FBS, after culture for 1, 2, and 3 days, The number of cells invading into matrigel were counted after
0.1% crystal blue staining. (E) Invasion tests were done in duplicate and average and SD were shown. *,p,0.01. (F) Spheroid cells formed colonies in
top agar detected in anchorage-independent growth assay (AIG) as shown under microscopy. 500 cells were seeded in 6 well plates containing a top
layer of 0.3% soft agar and 0.5% agar base in DMEM, 10% FBS. 24 hrs later, the number of cells seeded was determined by counting cells under the
light microscope. After 3 weeks of growth in soft agar, the number of colonies (Colonies .5 cells) were counted; 10 different fields were quantified
per well and the average number of colonies per field was calculated. The AIG index was expressed relative to the number of cells seeded. More than
70% of seeded spheroid cells formed colonies while none of seeded parent cells formed colonies. Experiments were repeated twice with similar
results. *,p,0.01. Error bars: SD.
doi:10.1371/journal.pone.0084941.g005
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non-stem cells while the small number of cells that survived the
chemotherapy treatment are resistant stem-like cells with more
proliferative potential compared to non-spheroid cells once
chemotherapy treatment was removed. To confirm this hypoth-
esis, we investigated clonogenecity of residual cells after Cisplatin
treatment. Spheroid cells and parent cells were treated with
increasing concentration of Cisplatin for 24 hr, washed and 300/
well of treated cells were cultured in 6-well-plate for another
10 days, the numbers of colonies (.5 cells) were counted under
microscopy. Untreated spheroid cells generated many colonies
while parent cells formed significantly less colonies, consistent with
our chemotherapy survival assays. As the Cisplatin concentration
increased, the number of colonies decreased. However, spheroid
cells still formed significantly more colonies than parent cells after
Cisplatin treatment (Fig. 6C).
Metabolism Studies Reveal Spheroid Cells’ Resistance to
Oxygen Deprivation
Cancer cells adopt an alternative metabolic pathway and
increase their glycolytic activity through a process called the
Warburg effect [41]. The Warburg effect is necessary for cancer
cells to resist oxidative stress and to adapt to hypoxic conditions
[42]. Since glycolysis could play an essential role in tumorigenesis
during both the immortalization and transformation steps [43], we
investigated the dynamic metabolic flux of spheroid cells. Lactate
secreted into cell culture medium can be used to measure label
incorporation into the three-carbon metabolite pool. Direct
[U-13C6] glucose catabolism through glycolysis results in m3
lactate, whereas passage through the oxidative and nonoxidative
branches of the pentose phosphate pathway of glucose results in
m2 lactate. As expected, the majority of lactate is produced via
glycolysis in all tumor cell cultures (Fig. 7A). Spheroid cells
showed significant increase in oxidizing glucose directly in the
pentose cycle (Fig. 7B). Metabolism flux comparison between
Glucose-6-P Dehydrogenase (G6PDH) and glycolysis revealed
increased pentose cycle flux and NADPH production in spheroid
cells, indicating increased acetate use for de novo fatty acid synthesis
instead of complete oxidation in spheroid cell cultures (Fig. 7C).
The 13C label enrichment of lactate from glucose in spheroid cells
showed a more than two fold increase compared with their parent
cells (Fig. 7D). The 13C isotopomer distribution showed a
significant increase in anaerobic glycolysis and defective aerobic
glucose metabolism in spheroid cells. This is indicative and
important marker of decreased tricarboxylic acid (TCA) cycle flux
and energy production via complete glucose/substrate oxidation.
TCA cycle anaplerotic flux was measured using the equilibrium
between glutamate and a-ketoglutarate. The large increase in
glutamate labeling in two carbon positions with 13C indicated a
defective TCA cycle and limited turnover of ketoglutarate into
succinate and fumarate (Fig. 7E). This indicates a complex-II
defect in spheroid cell cultures. Consistently, 13C-labeled carbon
dioxide release from glucose was significantly decreased in
spheroid cells (Fig. 7F), which also indicated that spheroid cells
have defects in complete glucose oxidation in the TCA cycle. 13C-
gultamate and acetyl-CoA are the transported products of the
citrate shuttle from mitochondria to the cytosol for de novo fatty
acid synthesis, fatty acid chain elongation and glutamate recycling.
Glutamate labeling in the cytosol is similar to that of malonyl-CoA
and fatty acids up to palmitate (C:16) via substrate sharing through
the citrate shuttle. 13C-acetate incorporation from substrate into
fatty acids and rate of new fatty acid synthesis, which corresponds
with the fraction of newly synthesized glutamate, was measured by
glutamate labeling in the cytosol. The fraction of newly
synthesized fatty acid increased significantly in spheroid cells
(Fig. 7G), and 13C enrichment of acetate for fatty acid synthesis
also showed significant increase (Fig. 7H). Spheroid cells had
significant increase in malonyl-CoA synthesis and fatty acid de novo
synthesis and breakdown via peroxisomal beta oxidation. The
large increase of glucose derived acetate used for malonyl-CoA
synthesis also indicated severe defect in TCA cycle energy
production and turnover. The main energy production and
biosynthetic metabolism pathways for both spheroid cells and
parent cells are summarized in Figure 7I.
Figure 6. Spheroid cells are resistant to chemotherapy in vitro. (A) More spheroid cells were killed by Cisplatin than parent cells. The same
numbers of spheroid and parent cells were cultured in CM with indicated amount of Cisplatin for 2 days and numbers of cells from different time
points were determined. (B) More parent cells survived after Cisplatin treatment for 48 h (Left). However, 8 days later, only spheroid cells were
growing while parent cells disappeared (Right). (C) Spheroid and parent cells were treated with indicated amount of Cisplatin for 24 h, washed, and
300 of survived cells/well were cultured in CM for another 10 days, cell colonies were shown after crystal violet staining. The same clonogenic survival
assays were repeated twice with similar results. Colonies formed (.5 cells) after 10 days of growth were counted and average and SD were shown.
*,p,0.05.
doi:10.1371/journal.pone.0084941.g006
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Figure 7. Spheroid cells show a hypoxia-resistant metabolism profile. Metabolic profiles of a normal ovarian cell line RPNLOv78 as control,
EOC cells RP-OV17534, and spheroid RP-OV17534 cells cultures in the presence of [U-13C6]glucose for 24 hrs (n = 3) showing (A) percentages of
m3-13C lactate derived directed from glycolysis; (B) percentages of m2-13C lactate derived from pentose cycle; (C) ratio of m2 to m3 lactate; (D)
percentage of 13C-labeled lactate of total lactate; (E) percentages of 13C-double-labeled glutamate in total 13C-labeled glutamate; (F) 13CO2 release
from [U-13C6]glucose; (G) The fraction of newly synthesized palmitate and the
13C enrichment of acetyl units (H). Error bars: SD; *,p,0.01, compared
with parental EOC cells. (I) EOC spheroid cells show increased anaerobic glycolysis, increased direct glucose oxidation in the pentose cycle, but low
TCA cycle carbon flux, low anaplerotic flux, and de novo fatty acid synthesis. In contrast, parent EOC cells show increased TCA cycle and high
anaplerotic flux. G6P, glucose-6-P; F6P, fructose-6-P; GAP, glyceraldehyde-3-P; 6PG, 6-P-gluconate; R5P, ribulose-5-P. Various thickness of lines
represent different strengths of metabolic flux.
doi:10.1371/journal.pone.0084941.g007
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Discussion
There are both single cells and spheroid cells in EOC tumors
and ascites [44,45]. Previous research in ovarian cancer has
focused mainly on the metastatic behavior of single cells.
Currently, there is data to demonstrate that spheroids are capable
of tumorigenesis in vivo, and have a reduced response to
chemotherapeutic drugs in vitro [46–48]. In order to study EOC
pathogenesis, we cultured EOC primary cells under stem cell-
selective conditions and generated anchorage-independent, self-
renewing spheroids morphologically similar to spheroids isolated
from patient ascites [5,6]. These spheroid cells expressed
numerous stem cell markers and were sustainable indefinitely
under stem cell-selecting conditions. The spheroid cells had
shorter doubling time than their parental cells and showed
additional attributes that are distinct from their parent cells.
Strikingly, as few as 2000 spheroid cells from primary tumor cells
engrafted into immune-deficient mice and allowed full recapitu-
lation of the original tumor, whereas .105 parent tumor cells
remained non-tumorigenic. These spheroid cells also could serially
propagate tumors of identical phenotypes in vivo. In order to
address concerns regarding engraftment into non-native microen-
vironment [29,30], we i.p. injected EOC spheroid cells into SCID
mice which resulted in a pathology essentially identical to the
human malignancy, with formation of bloody ascites and extensive
peritoneal dissemination. Although there is a long history of
transplanting human tumor cells into immune-deficient mice, the
strong host resistance in these mice allowed only the most
aggressive tumors and cell lines to be engrafted. Our in vivo
engraftment experiments not only indicated that spheroid cells are
highly tumorigenic but also that EOC is hierarchically organized
so that only a subset of cells-cancer stem cells- possess the potential
to initiate and sustain tumor growth.
Cell motility is one of the factors that contribute to tumor cell
invasion. Indeed, spheroid cells showed higher migration ability
than their parent cells both in migration and wound healing
assays. Importantly, spheroid cells had higher invasion ability than
parent cells in invasion assays. They also showed 3-D growth in
anchorage-independent growth assays. These results are consistent
with previous reports [5,7,49,50] indicating that spheroids could
adhere to, migrate on and infiltrate into other monolayer cells. In
addition, our data demonstrated that aggressive properties of
spheroid cells enriched with cancer stem cells contributes to
ovarian cancer pathogenesis.
Contrary to previous reports that spheroid cells are more
resistant to chemotherapy drugs [5–8], we demonstrated that
spheroid cells were initially more sensitive than parent cells to
cisplatin and paclitaxel treatment (Fig. 6 and data not shown).
However, our clonogenic survival assay indicated that more
spheroid cells survived after 24 hrs of cisplatin treatment,
compared with parent cells. This may be because spheroid cells
proliferate faster than parent cells in CM, and therefore more
dividing spheroid cells were killed by drug than their parent cells.
However, after drug removal, the surviving spheroid cells
recovered faster than parent cells. These two lines of evidence
suggested that a large fraction of spheroid cells killed by cisplatin
are more differentiated non-stem cells, while the small fraction of
spheroid cells that survived chemotherapy are cancer stem cells.
The stemness properties of these surviving spheroid cells was
demonstrated by their ability to generate more tumor colonies
than the large numbers of parent cells that survived from cisplatin
treatment. These results may explain why current chemothera-
peutic regimens are unable to achieve sustained remission in
ovarian cancer patients, despite frequently producing a complete
response at the time of first line treatment.
It has been shown that cancer cells use more glucose compared
to normal cells and accumulate extracellular lactate even in
normoxic conditions, a feature called Warburg effect [51,52]. In
addition, recent reports have shown that human pluripotent stem
cells rely mostly on glycolysis to meet their energy demands
[53,54]. Using stable 13C-glucose isotope, we demonstrated that
spheroid cells have a significant increase in glycolysis flux
compared to their parent cells (Fig. 7). This pattern of glycolytic
flux is similar to what has been observed for pluripotent stem cells
[53]. The very different patterns of substrate utilization likely
explain their aggressiveness and resistance to chemotherapies. Our
results indicate that spheroid cells mainly route glucose to
anaerobic glycolysis. This direct oxidation of glucose through
anaerobic glycolysis is in accord with recent publications
suggesting that CSCs may have even more active glycolytic
activity compared to the bulk of general cancer cells [55–58]. In
addition, we demonstrated that the amount of glucose utilized in
the pentose phosphate pathway is far greater than that oxidized
through the TCA cycle by spheroid cells. Since the oxidative
branch of the pentose cycle is an efficient means for producing
cytoplasmic NADPH and high NADPH production would be
necessary for increased fatty acid synthesis, a NADPH dependent
process, our data shows that synthesis of fatty acids are indeed
increased in spheroid cells. Since hypoxia is associated with the
formation and maintenance of cancer stem cells [59], our
metabolic data suggest that ovarian CSCs are likely to survive in
severely hypoxic microenvironments. These spheroid cell meta-
bolic attributes may confer the increased chemoresistance
observed in this study. On the contrary, parent cells display
increased use of anabolic pathways to the detriment of anaerobic
glycolysis and are likely to be more vulnerable to chemotherapy.
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